President Donald Trump’s approval rating on marijuana policy remains largely underwater among cannabis consumers, according to the latest quarterly NuggMD-Marijuana Moment tracking poll. And while many stakeholders were encouraged to see the president share a video touting the health benefits of CBD, a majority of consumers don’t see it as an indication the administration will be moving forward with cannabis rescheduling.

The quarterly approval survey, as well as a separate flash poll that followed Trump’s CBD post, indicate that, without meaningful action on marijuana rescheduling, many consumers remain skeptical that reform action is imminent—despite the president’s commitment in late August to decide on the issue within weeks.

All told, a 47 percent plurality of cannabis consumers said they have no opinion or a neutral view of Trump’s marijuana policy actions as of the third quarter of 2025. Another 42 percent said they either disapprove or strongly disapprove, while 11 percent said they approve or strongly approve.

That does represent a 4 percentage point improvement in approval from the last quarter, but it remains the case that disapproval outweighs approval by a substantial margin. That could be related to the fact that, while Trump during his campaign last year endorsed rescheduling—as well as marijuana industry banking access—the administration has not yet implemented such reforms so far in his second term.

Among self-identified Republicans who use marijuana, Trump’s cannabis policy approval rating plummeted over the last quarter—from net approval/disapproval at 57.2 percent in the second quarter of 2025 to -1.9 percent in the latest quarter.

Andrew Graham, head of communications at NuggMD, told Marijuana Moment that “there’s really no sugar-coating a drop that big.”

“I would not read this as evidence that millions of Republicans are no longer supporting POTUS because of cannabis policy,” he acknowledged, but said he “would read this as evidence that the lack of progress on cannabis reform is irking Republicans who use the plant, and that, on this issue, POTUS does not have the political durability that he has proven to have on other issues.”

“It’s pretty clear, in retrospect, that this portion of the president’s base was animated by promises he made on rescheduling and his support for adult-use in Florida, which ultimately failed,” he said, referencing a state legalization initiative Trump backed on the campaign trail. “Both of those things made news and were part of his 2024 re-election campaign.”

Notably, however, the president’s approval on cannabis policy did increase among Democrats and unaffiliated marijuana consumers in the survey as compared to last quarter. Trump’s August comments signaling a forthcoming rescheduling decision “probably drove much of that movement, even though the timeline the White House floated hasn’t been followed,” Graham said.

The poll, which involved interviews with 561 cannabis consumers who live in states with legal markets from August 29 to September 24 and has a ±4.14 percentage point margin of error, also asked respondents whether they’d be more or less likely to support the administration if rescheduling or legalization was implemented.

About 57 percent said they’d be more inclined to support the administration if those reforms were enacted, compared to 43 percent who said it wouldn’t change their view and less than 1 percent who said they’d have a less favorable opinion of the administration.

Overall, “the data shows inaction on cannabis policy is costing the president significant political capital,” Graham said. “The portion of his base who consumes cannabis numbers in the tens of millions, and more cannabis consumers currently live in red states than in blue states. Around one in three is politically unaffiliated. It’s a significant audience that, contrary to the stereotype, is not particularly progressive.”

The latest quarterly survey was conducted shortly befor the president posted on his Truth Social account a video from The Commonwealth Project that touted the health benefits of CBD, particularly for senior citizens. Some in the industry viewed that as a bellwether of a pro-rescheduling decision soon-to-come.

To account for that potential factor, NuggMD ran a separate flash poll in partnership with Marijuana Moment that specifically inquired among cannabis consumers whether they felt the video share signaled it was more or less likely that Trump would be advancing the proposal to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA).

That survey—which involved interviews with 415 respondents from October 2-7, with a 4.8 percentage point margin of error—found that more than half of marijuana users feel the social media post “does not mean anything in the context of rescheduling.”

About 37 percent said that the post meant rescheduling either will happen or is more likely to happen, while 13 percent said it signaled the reform would not happen or was less likely to happen.

“This data, and our quarterly presidential approval poll more broadly, suggests that the president does not have the political durability on cannabis that he has on other issues,” Graham said. “I don’t think he can kick the can down the road on rescheduling without alienating the portion of his base that uses the plant, because they’re expecting real action.”

Meanwhile, several GOP senators recently told Marijuana Moment that, if Trump ultimately moves forward with marijuana rescheduling, it would be a “game changer” for future federal cannabis reform.

One of Trump’s longtime advisors, Roger Stone, separately said that his administration has an opportunity to move forward with marijuana rescheduling—or, even broader legalization—in a way that Democrats who regularly tout the reform failed to achieve when they controlled the White House and Congress.

The Republican Senate sponsor of a bipartisan cannabis banking bill said recently that Trump rescheduling marijuana would be an “important domino” to advance his legislation.

Whether Trump ultimately decides to move forward with rescheduling remains to be seen. Despite his endorsement of the policy change on the campaign trail ahead of his election for a second term, he declined to restate that support when asked about it during a briefing late last month—even though he did say a decision would come within weeks.